Cellceutix Autism Research Demonstrates Increase In Serotonin Levels In Three Areas Of The Brain
Main Category: AutismAlso Included In: Neurology / Neuroscience
Article Date: 24 Jun 2010 - 4:00 PDT
'Cellceutix Autism Research Demonstrates Increase In Serotonin Levels In Three Areas Of The Brain'
| Patient / Public: | ![]() |
|
| Healthcare Prof: | ![]() |
3 (2 votes) |
| Article opinions: | 1 posts |
Cellceutix Corporation (OTCBB: CTIX) is pleased to announce that they have completed another study in the research of KM-391, their novel compound being developed to treat the core symptoms of autism. Cellceutix is pioneering research in autism treatments and has been making solid progress with pre-clinical research as announced in previous press releases.
Neonatal serotonin depletion and decreased brain plasticity are established observations in the autistic brain. The Cellceutix team has identified a reliable animal model and has been successful in chemically inducing these characteristics in the model. The data collected to this point has been promising as KM-391 has shown to be successful in altering the serotonin and brain plasticity levels resulting in physical and behavioral changes in the model that are similar to the "non-autistic" control groups.
The latest research involved physical measurements of serotonin levels in the cerebral cortex, hippocampus, and caudate nucleus areas of the brain. Several groups of rats were established with two of the groups being injected to induce the symptoms of autism. After 48 days, the brains were assayed for serotonin by ELISA with the data showing that the administration of KM-391 significantly increased serotonin levels in all 3 regions of the brain: cerebral cortex, hippocampus, and caudate nucleus, from very low levels as observed with the induced autism to normal levels as observed in placebo treated control which received no treatment.
George Evans, Cellceutix Chief Executive Officer, commented, "This new data is highly relevant as it reinforces the data from previous studies and further solidifies our contention that serotonin levels in multiple brain regions may be a necessary key to the next generation of autism treatments."
Source:
Cellceutix Corporation
Visit our autism section for the latest news on this subject.
MLA
25 May. 2012. <http://www.medicalnewstoday.com/releases/192827.php>
APA
http://www.medicalnewstoday.com/releases/192827.php.
Please note: If no author information is provided, the source is cited instead.
Visitor Opinions (latest shown first)
Revolutionary Autism Research
posted by OTC Showcase on 19 Jul 2010 at 8:40 amThere are not many companies that have any significant developments in the new wave of autism research. Cellceutix is a company that I am regularly in contact with to stay abreast on developments both by them and in the industry. They are truly ahead of the pack in this industry and providing hope for all affected by autism.
Add Your Opinion On This Article
'Cellceutix Autism Research Demonstrates Increase In Serotonin Levels In Three Areas Of The Brain'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.






